HC Wainwright & Co. Maintains Buy on Dianthus Therapeutics, Raises Price Target to $158

Benzinga Newsdesk www.benzinga.com Positive 79.4%

Neg 0% Neu 0% Pos 79.4%

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Buy and raises the price target from $130 to $158.